Click here to VIEW our publications
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseasese.
Woman's Husband's Health Journey Inspires Everything ALS
NBC10’s Erin Coleman speaks to Everything ALS founder Indu Navar about her husband’s own ALS diagnosis and how the group is working to better ALS research. You can help the fight through Everything ALS or at the 2022 Walk to Defeat ALS.
Non-profit conducts study to diagnose ALS quicker
LANSING, Mich. (WLNS) — In the 150 years since ALS was discovered there is still no cure or single test to diagnose the disease.
The demand for more answers is what drove one woman to start up her own non-profit.
EverythingALS began its research in 2021 and now they’re working toward diagnosing the disease faster.
“I really want to help people who are going through this disease,” said Indu Navar, Founder of EverythingALS.
The study analyzes data when it comes to physiological changes and the progression of the disease.
Navar says she wants to shift the focus to the brain, something she believes isn’t understood well enough.
Q&A With Indu Navar, founder of Everything ALS
Indu Navar, founder of Everything ALS, speaks with Pharm Exec about how she lost her husband to the disease and how she's trying to improve the way its diagnosed.
Diagnosing ALS is a difficult process for patients experiencing symptoms. After the death of her husband, tech entrepreneur Indu Navar founded Everything ALS, and organization she hopes will refine and improve the way ALS and other neurological conditions are diagnosed.
New technology helping ALS patients in Louisiana
BATON ROUGE, La. (BRPROUD) — ALS, often called Lou Gehrig’s disease, is a progressive motor neuron disease that gradually robs people of their ability to walk, talk, swallow, and eventually breathe.
Indu Navar, the founder of EverythingALS, said, “ALS has no known cause or cure and so patients suffer for years not knowing what is wrong and have to go through rigorous testing and a process of elimination to finally get diagnosed. If they are diagnosed, there are no treatments. Life expectancy is two to five years.”
EverythingALS Joins Forces with Aural Analytics, FeetMe, ZEPHYRx and Others for a First-Of-Its-Kind ALS Research Study
SAN FRANCISCO (PRWEB) SEPTEMBER 19, 2022
EverythingALS, a patient-focused non-profit that brings together people living with ALS, caregivers, physicians, researchers, and pharmaceutical companies to collaborate on an open innovation platform using cutting-edge technologies and data science to improve progression measurements for neurological disease like Amyotrophic Lateral Sclerosis (ALS), has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS...
Groundbreaking research involving artificial intelligence could diagnose ALS patients sooner
Five thousand people in the U.S. are diagnosed with a neurological disease called ALS every year. Medical experts say it typically takes an average of two years to diagnose, but new research will likely make that timetable a lot shorter.
In 2019, Mark Weston and his wife, Kathleen, had their retirement all planned out.
"We were all set up for a sail off into the sunset and have a really fun retirement," Weston said. "We had, we bought a house on the coast of Maine several months earlier."
A week before the big move, he got a life-changing diagnosis.
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments
LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS, a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS.
‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients
EverythingALS aims to speed drug development through improved diagnostics.
in 2016, Indu Navar’s husband, Peter Cohen, experienced the first symptom of what turned out to be amyotrophic lateral sclerosis (ALS), a progressive degenerative disease commonly known as Lou Gehrig’s disease.
EverythingALS founder Indu Navar
Permission granted by EverythingALS/Indu Navar
“His foot was just acting weird,” says Navar, who founded the California nonprofit EverythingALS two years ago. “We didn’t know where to go, so we went to a chiropractor,” she says.
Healthbeat: New ALS research driven by patient-focused non-profit
SCRANTON, LACKAWANNA COUNTY— New research is underway to better understand and treat ALS, a difficult disease to diagnose with no known cure. ALS patient Paul Miller of Scranton is one of the participants.
The progressive neurodegenerative disease ALS affects as many as 30,000 Americans. There is no known cure despite efforts to better understand it and treat it.
ALS is a puzzling disease for certain with so much needing to be learned about it.
TOMMY EDWARD CULPEPPER,Jr
Bentonville man works to help diagnose ALS sooner
A Bentonville man is dedicating his life to advocating for people with ALS and trying to help diagnose the disease sooner.
“I’m a movie connoisseur,” said Tommy Edward Culpepper, Jr. “I love movies.”
For Culpepper, movies have always been his saving grace. Even when he was a kid growing up in St. Louis, Missouri.
“I grew up in the Peabody Projects and the home environment wasn’t the greatest,” he said. “Star Wars, Blade Runner, Highlander. Movies like that are excellent getaways for me.”
Until he found himself in a nightmare that started in the doctor’s office...
These 2 Surprising Traits May Predict ALS, New Research Says
How ALS researchers are using an intriguing tool to learn keys of this disease that has at times taken years to diagnose. Plus, one woman's story of why she agreed to participate in this research
Amyotrophic lateral sclerosis (sometimes called Lou Gherig’s disease, or ALS) affects around 15,000 Americans, with about 5,000 receiving a new diagnosis each year, according to the Centers for Disease Control and Prevention.